Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

EyePoint Pharmaceuticals : Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

07/01/2021 | 07:01am EDT

WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced today that the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU.

“We are pleased by the AMA’s approval of this new Category III code, which we believe will provide physicians with an opportunity for a reimbursement pathway for intraocular procedures, including DEXYCU,” said Scott Jones, Chief Commercial Officer of EyePoint Pharmaceuticals. “DEXYCU is the first and only FDA-approved, single dose, sustained-release, intracameral steroid for the treatment of postoperative inflammation. We believe the new code is an important step toward increased adoption of DEXYCU.”

Category III CPT codes are temporary codes for emerging technologies, services and procedures intended to be used for specific data collection or documentation. Inclusion or exclusion of a procedure or service does not imply any health insurance coverage or reimbursement policy.

About EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential twice-yearly intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ®, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU®, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts. To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding the anticipated use of proceeds for the proposed offering and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause EyePoint’s actual results to be materially different than those expressed in or implied by EyePoint’s forward-looking statements. For EyePoint, this includes the continued impact of the COVID-19 pandemic on EyePoint’s business, the medical community and the global economy and the impact of general business and economic conditions, our expectations regarding the timing and clinical development of our product candidates, including EYP-1901; and the potential for EYP-1901 as a novel twice-yearly treatment for serious eye diseases, including wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ and DEXYCU and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.


Christina Tartaglia
Stern IR
Direct: 212-698-8700

Media Contact

Green Room Public Relations
Caren Begun
Green Room Communications
Direct: (201) 396-8551 

Primary Logo

Source: EyePoint Pharmaceuticals, Inc.

2021 GlobeNewswire, Inc., source Press Releases

09/07EYEPOINT PHARMACEUTICALS : Announces Participation at Upcoming Investor Conferen..
08/17EYEPOINT PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
08/12EYEPOINT PHARMACEUTICALS : EYPT Investor Presentation August 2021
08/10EYEPOINT PHARMACEUTICALS : to Present at the H.C. Wainwright Ophthalmology Virtu..
08/09EYEPOINT PHARMACEUTICALS : Files for Up to $350 Million Mixed-Securities Shelf
08/06EYEPOINT PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
08/04EYEPOINT PHARMACEUTICALS : Q2 Earnings Snapshot
08/04EYEPOINT PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Hig..
08/04EYEPOINT PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
08/04Eyepoint Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarte..
More news
Analyst Recommendations on EYEPOINT PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 36,7 M - -
Net income 2021 -46,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,07x
Yield 2021 -
Capitalization 290 M 290 M -
Capi. / Sales 2021 7,89x
Capi. / Sales 2022 5,35x
Nbr of Employees 100
Free-Float 87,4%
Duration : Period :
EyePoint Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EYEPOINT PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Last Close Price 10,08 $
Average target price 21,20 $
Spread / Average Target 110%
EPS Revisions
Managers and Directors
Nancy Sue Lurker President, Chief Executive Officer & Director
George O. Elston CFO & Head-Corporate Development
Göran Albert Torstensson Ando Non-Executive Chairman
Dario A. Paggiarino Chief Medical Officer & Senior Vice President
Jay S. Duker Chief Strategic Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE335.78%85 800
WUXI APPTEC CO., LTD.26.24%64 886